These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 18430270)
1. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Athyros VG; Kakafika AI; Papageorgiou AA; Paraskevas KI; Tziomalos K; Anagnostis P; Pagourelias E; Koumaras C; Karagiannis A; Mikhailidis DP Curr Med Res Opin; 2008 Jun; 24(6):1593-9. PubMed ID: 18430270 [TBL] [Abstract][Full Text] [Related]
2. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A; Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187 [TBL] [Abstract][Full Text] [Related]
3. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin. Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M; Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541 [TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
5. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP; Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H; Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. Koren MJ; Hunninghake DB; J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006 [TBL] [Abstract][Full Text] [Related]
8. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229 [TBL] [Abstract][Full Text] [Related]
9. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061 [TBL] [Abstract][Full Text] [Related]
10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. Leibovitz E; Harats D; Gavish D Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409 [TBL] [Abstract][Full Text] [Related]
12. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis. Kuryata OV; Yegorova YV Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629 [TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V; Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940 [TBL] [Abstract][Full Text] [Related]
14. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Farsang C; Athyros V; Gaw A; Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Jones PH; McKenney JM; Karalis DG; Downey J Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH). McPherson R; Angus C; Murray P; Genest J; Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326 [TBL] [Abstract][Full Text] [Related]
18. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Athyros VG; Papageorgiou AA; Mercouris BR; Athyrou VV; Symeonidis AN; Basayannis EO; Demitriadis DS; Kontopoulos AG Curr Med Res Opin; 2002; 18(4):220-8. PubMed ID: 12201623 [TBL] [Abstract][Full Text] [Related]
19. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK; J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899 [TBL] [Abstract][Full Text] [Related]
20. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. Waters DD; LaRosa JC; Barter P; Fruchart JC; Gotto AM; Carter R; Breazna A; Kastelein JJ; Grundy SM J Am Coll Cardiol; 2006 Nov; 48(9):1793-9. PubMed ID: 17084252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]